Koçak Ulucaköy Rezan, Kılıç Ayza, Batıbay Sevilay, Çobanoğlu İdil Melis, Yıldırım Öztürk Elif Nur, Günendi Zafer, Sepici Dinçel Aylin, Göğüş Feride Nur
Department of Rheumatology, Ministry of Healthy, Ankara City Hospital, Ankara, Türkiye.
Department of Physical Medicine and Rehabilitation, Gazi University Faculty of Medicine, Ankara, Türkiye.
Arch Rheumatol. 2024 Mar 20;39(3):368-374. doi: 10.46497/ArchRheumatol.2024.10360. eCollection 2024 Sep.
The aim of this cross-sectional study was to investigate if serum levels of granulocytemacrophage colony-stimulating factor (GM-CSF) and CC chemokine ligand 17 (CCL17) correlate with disease activity in axial spondyloarthritis (axSpA) and peripheral spondyloarthritis (pSpA) patients.
The cross-sectional study was conducted with 80 individuals (48 females, 32 males; mean age: 47.7±11.5) between March 2021 and September 2021. Of the participants, 20 were axSpA, 20 were pSpA, and 20 were active rheumatoid arthritis patients, and the remaining 20 were healthy controls. Age, sex, body mass index, disease duration, comorbid diseases, smoking status, medical treatments, C-reactive protein (CRP) level and human leukocyte antigen B27 (HLA-B27) positivity were recorded. Serum GM-CSF and CCL17 levels were analyzed by ELISA. Ankylosing Spondylitis Disease Activity Score with CRP (ASDAS-CRP) was used to evaluate the disease activity of patients with spondyloarthritis. Functional status of spondyloarthritis patients was evaluated by Bath Ankylosing Spondylitis Functional Index (BASFI).
While the serum GM-CSF levels were similar in the axSpA and pSpA groups, they were significantly higher than the healthy control group (p=0.021 and p=0.009, respectively). There was a significant correlation between GM-CSF levels and ASDAS-CRP (r=0.545, p=0.013) and BASFI (r=0.546, p=0.013) in the axSpA group. In active axSpA patients, the cut-off value for GM-CSF was 15.89 pg/mL (sensitivity 50%, specificity 100%). No differences were detected in serum CCL17 levels among the groups.
The results suggest that serum GM-CSF levels may be used as a new marker for the evaluation of disease activity in axSpA, and GM-CSF might be a therapeutic target.
本横断面研究旨在调查粒细胞巨噬细胞集落刺激因子（GM-CSF）和CC趋化因子配体17（CCL17）的血清水平是否与轴性脊柱关节炎（axSpA）和外周脊柱关节炎（pSpA）患者的疾病活动相关。
本横断面研究于2021年3月至2021年9月对80名个体（48名女性，32名男性；平均年龄：47.7±11.5岁）进行。参与者中，20名为axSpA患者，20名为pSpA患者，20名为活动性类风湿关节炎患者，其余20名为健康对照。记录年龄、性别、体重指数、病程、合并疾病、吸烟状况、治疗情况、C反应蛋白（CRP）水平和人类白细胞抗原B27（HLA-B27）阳性情况。采用酶联免疫吸附测定（ELISA）法分析血清GM-CSF和CCL17水平。使用基于CRP的强直性脊柱炎疾病活动评分（ASDAS-CRP）评估脊柱关节炎患者的疾病活动度。采用巴斯强直性脊柱炎功能指数（BASFI）评估脊柱关节炎患者的功能状态。
axSpA组和pSpA组的血清GM-CSF水平相似，但均显著高于健康对照组（分别为p = 0.021和p = 0.009）。axSpA组中，GM-CSF水平与ASDAS-CRP（r = 0.545，p = 0.013）和BASFI（r = 0.546，p = 0.013）之间存在显著相关性。在活动性axSpA患者中，GM-CSF的临界值为15.89 pg/mL（敏感性50%，特异性100%）。各组间血清CCL17水平未检测到差异。
结果表明，血清GM-CSF水平可作为评估axSpA疾病活动度的新标志物，GM-CSF可能是一个治疗靶点。
